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Medulloblastomas (MBs) are the most common brain tumors in
children. Some are thought to originate from cerebellar granule
neuron progenitors (GNPs) that fail to undergo normal cell cycle
exit and differentiation. Because microRNAs regulate numerous
aspects of cellular physiology and development, we reasoned that
alterations inmiRNA expressionmight contribute toMB.We tested
this hypothesis using 2 spontaneous mouse MB models with
specific initiating mutations, Ink4c/; Ptch1/ and Ink4c/;
p53/. We found that 26 miRNAs showed increased expression
and 24 miRNAs showed decreased expression in proliferating
mouse GNPs and MBs relative to mature mouse cerebellum, re-
gardless of genotype. Among the 26 overexpressed miRNAs, 9
were encoded by themiR-1792 cluster family, a group of microR-
NAs implicated as oncogenes in several tumor types. Analysis of
human MBs demonstrated that 3miR-1792 cluster miRNAs (miR-
92, miR-19a, and miR-20) were also overexpressed in human MBs
with a constitutively activated Sonic Hedgehog (SHH) signaling
pathway, but not in other forms of the disease. To testwhether the
miR-1792 cluster could promote MB formation, we enforced
expression of these miRNAs in GNPs isolated from cerebella of
postnatal (P) day P6 Ink4c/; Ptch1/ mice. These, but not
similarly engineered cells from Ink4c/; p53/ mice, formed
MBs in orthotopic transplants with complete penetrance. Interest-
ingly, orthotopic mouse tumors ectopically expressing miR-1792
lost expression of the wild-type Ptch1 allele. Our findings suggest a
functional collaboration between themiR-1792 cluster and the SHH
signaling pathway in the development of MBs in mouse and man.
cerebellum  microRNAs  oncomiR1  granule neuron progenitors
Medulloblastoma (MB), the most common pediatric malig-nant brain tumor, arises in the cerebellum with at least a
subset originating from cerebellar granule neuron progenitor
(GNP) cells that fail to properly migrate and differentiate (1, 2).
Two inherited cancer syndromes induce MB in humans. Gorlin
syndrome is characterized by skeletal abnormalities and large
body size in combination with a high incidence of basal cell
carcinoma and MB (3). Gorlin patients have mutations in
PATCHED (PTCH), the receptor for Sonic Hedgehog (SHH) (4,
5, 6, 7). SHH is the major mitogen for GNP proliferation (8) and
mutations in the SHH pathway induce MB in mice (9, 10).
Turcots’s syndrome is associated with colon cancer and malig-
nant neuroepithelial brain tumors resulting from mutations of
the adenomatous polyposis coli (APC) gene. APC is a member
of the wingless (WNT) signaling pathway that regulates the
proliferation and fate of neural progenitor cells (11, 12).
Both SHH/PTCH and WNT pathways have also been impli-
cated in sporadic disease. Recent studies of a cohort of 46 St.
Jude patients identified 5 distinct MB subgroups, on the basis of
mRNA and genomic profiling. Two of these containedmutations
that activate the SHH/PTCH (25%) andWNT (20%) signaling
pathways, respectively (13).
The past several years have produced a strong appreciation
that changes in noncoding RNAs can also impact tumorigenesis.
MicroRNAs are endogenous triggers of the RNAi pathway.
These 21–23 nucleotide (nt) RNAs are matured through a 2-step
biogenesis mechanism from long, RNA polII transcripts (14).
While some microRNAs are encoded from individual transcrip-
tion units, others reside within introns of protein coding genes
or exist as polycistrons that generate multiple microRNAs from
a single primary transcript. MiRNAs reduce protein synthesis
following recognition of the 3 untranslated region (3-UTR) of
target genes viaWatson–Crick base pairing interactions (15). Many
miRNAs are conserved throughout evolution, suggesting that they
perform fundamental biological functions during development.
Currently 678 human miRNAs and 472 mouse miRNAs have
been confidently identified (miRBASE) (16). MicroRNAs have
been linked to the initiation, progression, and metastasis of
human malignancies, with some species displaying oncogenic
and others tumor suppressive potential (17). MiRNAs are often
expressed aberrantly in tumors as compared to normal tissues
and are likely to contribute to tumorigenesis by dysregulating
critical target genes (18).
ThemiR-1792 cluster, also calledOncomir-1, was among the
first miRNAs to be validated as showing oncogenic potential
(19). The cluster has 2 paralogs, miR-106a363 and miR-
106b25, that are located on different chromosomes and con-
tain individual miRNAs that are highly similar to those encoded
by the miR-1792 cluster. Despite their similarities, each of
these miRNA clusters has distinct functions (20, 21). For exam-
ple,miR-1792 alone is involved in B cell lymphomagenesis and
in lung development (21).
We hypothesized that miRNAs might play an important role
in normal cerebellar development and that dysregulation of
miRNAs might contribute to MB formation. We found that
miR-1792 is expressed in the developingmouse cerebellum and
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in proliferating GNPs but not in postmitotic differentiated
neurons. The miR-1792 cluster is overexpressed in mouse and
human MBs with an aberrantly activated SHH/PTCH signal
pathway. Moreover, enforced expression of miR-1792 in P6
Ink4c/; Ptch1/ GNPs induced MBs with complete pen-
etrance after orthotopic transplant into the brains of recipient
immunocompromised animals. These results provide the first
evidence that the SHH/PTCH signaling pathway and miR-
1792 functionally interact and contribute to MB development
in mice and man.
Results
The miR-1792 Cluster Family Is Expressed During Mouse Cerebellar
Development and in Mouse MBs.We performed unbiased Illumina
deep sequencing and subsequent comparative expression anal-
ysis of small RNAs isolated from P6 and 1 month (M) wild-type,
Ink4c/; p53/ or Ink4c/; Ptch1/ cerebella and GNPs
purified from these tissues. These time points were chosen to
coincide with the peak of proliferation of GNPs (P6) and with
completion of cerebellar development (1M). miRNAs expres-
sion signatures of these tissues were compared with profiles
generated from GNP-like tumor cells purified from MBs occur-
ring spontaneously in Ink4c/; Ptch1/ or Ink4c/;
p53/ mice (22) (Fig. 1).
Twenty-four miRNAs were expressed at higher levels in
1-month-old cerebella relative to P6 GNPs and MBs. These
miRNAs might act as tumor suppressors and/or as regulators of
genes that block differentiation. Among these was miR-124a,
which increases during neuronal differentiation under the con-
trol of the repressor element-1 silencing transcription factor
(REST) complex (23). Also showing greater abundance in post-
mitotic neurons was miR-138, a microRNA that was found to be
expressed exclusively in neuronal tissues (24), and miR-128, that is
highly expressed in the adult brain (25). Several miRNAs from 2
large clusters on mouse chromosome 12 were coordinately upregu-
lated: miR-300,381,487b,382 and miR-433,127,434,136.
Fig. 1. MiRNA signature during cerebellar development and in mouse MB models. Illumina deep sequencing reveals 50 miRNAs differentially expressed in
whole 1-month-old and P6 cerebella, and in purified P6 GNPs from cerebella of wild-type (WT), Ink4c/; Ptch1/ , Ink4c/; p53/ mice, or in MBs (red)
from both genotypes. Tumor and P6 GNP samples, considered together, were contrasted against adult cerebella and miRNAs were filtered to require a 1% FDR
and a 4-fold change between the groups.











In contrast, 26 miRNAs showed lower expression in 1-month-
old cerebella relative to P6 GNPs and mouse MBs regardless of
their genotypes. Among this group might be miRNAs that act as
oncomiRs (Fig. 1). Remarkably, 9 members of this group were
encoded by the miR-1792 cluster and its paralogs (20). We
found high expression of the miR-1792 and miR-106b25
paralog clusters (Figs. 1, 2,and Fig. S1). In contrast, the miR-
106a363 cluster encoded on mouse and human chromosome X
was weakly expressed (Fig. 2 and Fig. S1). Although expression
of individual miRNAs within the miR-106a363 cluster was 2
times higher in P6 GNPs and MBs compared to 1-month-old
cerebella, overall levels remained very low compared to the
paralogous clusters (Fig. 2 and Fig. S1). Because the pairs of
miRNAs 19b-1 and 19b-2 and miRNAs 92–1 and 92–2 have
identical sequences, we could not evaluate whether their expres-
sion came from the miR-1792 or the miR-106a363 cluster.
Additionally, the miRNA signature obtained in P6 GNPs and
GNP-like tumor cells versus differentiated neurons was similar
in wild-type, Ink4c/; Ptch1/ , and Ink4c/; p53/
mice. These findings suggest that the miRNA signature that we
obtained was characteristic of GNPs and that mutations in p53,
Ptch1 and Ink4c have little influence on miRNA expression in
this cell type under the conditions tested.
The Human MB Subgroup with an Activated SHH/PATCHED Signaling
Pathway Overexpresses miRNAs from the miR-1792 Cluster.Mouse
and human tumors that contain an activated SHH/PTCH path-
way share similar global gene expression signatures (26, 13). We
therefore tested whether human tumors with an activated SHH/
PTCH pathway also upregulate the miR-1792 cluster. We
performed quantitative real-time reverse transcriptase PCR
(QRT-PCR) analysis of miRNAs in 5 normal control cerebella
(generously provided by James Olson, Seattle, Washington) and
10 previously characterized human MBs (13) (Fig. 3). RNA
isolated from P6 mouse GNPs was used for comparison. Among
the MB samples, 5 tumors (MBs 102, 109, 142, 152, and 154)
displayed a gene expression signature characteristic of an acti-
vated SHH/PTCH pathway; 3 of these (MBs 142, 152, and 154)
contained inactivating mutations in PTCH. The 5 other human
MBs did not display an activated SHH/PTCH signature, nor did
they contain mutations in PTCH, SMOOTHENED (SMO), or
SUFU (13). miR-19a (P  0.003), miR-92 (P  0.001), and
miR-20a (P 0.008) showed increased abundance specifically in
MBs displaying the activated SHH/PTCH pathway signature
over those showing a nonactivated SHH pathway (P  0.026)
(Fig. 3). These results implicate the miR-1792 cluster in the
formation of human MBs that are driven by an aberrant SHH/
PTCH pathway and suggest a functional relationship between
Patched signaling and miR-1792.
Enforced Expression of miR-1792 in GNPs from Ink4c/; Ptch1/
Mice Accelerates MB in Vivo. To determine whether expression of
the miR-1792 cluster can lead to oncogenic transformation of
primary P6 GNPs, we enforced the expression of the entire
cluster in primary GNPs purified from the cerebella of P6
Ink4c/; p53/ and Ink4c/; Ptch1/ mice. These mice
normally spontaneously develop MBs within 5 months of life.
GNPs were infected with mouse stem cell virus (MSCV)-based
retroviruses encoding the miRNA cluster along with green
fluorescent protein under the control of the SV40 promoter
(MLS). Cells were injected immediately into the cortices of
immunocompromised naïve recipient mice without prior cell
Fig. 2. The miR-1792 cluster family is differentially expressed in proliferating GNPs and GNP-like tumor cells compared to postmitotic 1-month-old cerebella.
Schematic expression profiles of the 3 miRNA clusters reveals increasing levels of the miR-1792 cluster family in proliferating GNPs and GNP-like tumor cells.
Expression levels as sequencing read counts are indicated as color-scaled boxes. Each profile as a group was an average of multiple samples. Expression levels
of miR-124a and miR-21, nonmembers of the miR-1792 cluster family, are shown as controls. wc, whole cerebellum; WT, wild type.
Fig. 3. Human MBs with a SHH/PATCHED gene signature express individual
miRs from the miR-1792 cluster. Quantitative RT-PCR analysis of selected
microRNAs from themiR-1792 cluster using RNA extracted from human MBs,
purified GNPs from P6 mice, and normal human cerebella tissue. MB tumor
patient samples were previously molecularly characterized (13).
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culture (27). All (9/9 injections) populations of Ink4c/;
Ptch1/ GNPs, but none (0/4 injections) from Ink4c/;
p53/ mice transduced with human hsa-miR-1792 cluster
formed tumors, with a latency of 1.5 to 5 months (Table 1).
Promotion of MB development was specific to themiR-1792
cluster. Enforced expression of the miR-106a92 cluster or
oncomiR miR-21 (28) failed to induce MBs. (Table 1). When
infected with retroviruses carrying N-Myc, c-Myc, or cyclins D1
or D2, GNPs from Ink4c/; p53/ mice formed MBs with
the same efficiency as those from Ink4c/, Ptch1/ animals,
suggesting that they were competent for transformation (Table
1). Histopathologic analysis of excised tumors characterized
them as MBs with a characteristic biphasic pattern found in
human MBs (Fig. S2). The majority of tumor cells were GFP
positive, suggesting that they were retrovirally infected. We
confirmed by QRT-PCR that these tumor cells expressed the
miR-1792 cluster at elevated levels and found thatmiR-19a and
miR-92 were expressed in engineered tumors (Fig. 4A). QRT-
PCR analysis also revealed that all miR-1792 engineered
tumors lost expression of the wild-type Ptch1 allele, demonstrat-
ing that Patched1 is a bona fide tumor suppressor in engineered
and spontaneously derived MBs (Fig. S3). Finally miR-1792-
induced tumors expressed high levels ofMath1 andGli1mRNAs
(Fig. 4B). Together, these findings demonstrated that the Shh/
Patched signaling pathway was constitutively activated in these
engineered MBs.
GNP-like tumor cells are sensitive to cyclopamine, an inhibitor
of SHH pathway signaling (29). We found that tumor cells from
miR-1792 expressing MBs were also sensitive to cyclopamine,
which decreased their proliferation to the same extent as it
affected P6 GNPs or tumor cells from spontaneously derived
MBs (Fig. 4C, Left panel). In addition, as expected, Math1 and
Gli1 expression were concomitantly downregulated following
treatment (Fig. 4C, Right panel).
Finally, we addressed whether any of the reported miR-1792
targets were downregulated in MBs. When we compared the
protein levels of PTEN, p27Kip1, p130, and E2F-1 from purified
tumor cells from miR-1792-induced MBs with those in purified
GNPs fromP6 cerebella, 1-month-old cerebella, and purified tumor
cells from spontaneous tumors, we were unable to convincingly
show that these reported miR-1792 targets were affected by its
overexpression (data not shown).
Discussion
We have characterized the miRNA expression pattern during
mouse cerebellar development and in MBs from 2 mouse
models. A comparison of proliferating GNPs from P6 wild-type
and tumor-prone mice and tumor cells to postmitotic differen-
tiated neurons revealed 26 miRNAs that showed increased
expression and 24 miRNAs that showed decreased expression.
Among the 26 overexpressed miRNAs, 9 were encoded by the
miR-1792 cluster or its paralogs. As we observed for mouse
MBs, the subset of human MBs with a SHH signature also
overexpress miRNAs from the miR-1792 cluster. Ectopic
overexpression of this cluster, but notmiR-21, another oncomiR,
in proliferating GNPs from P6 Ink4c/, Ptch1/ animals
causes mice to develop MBs with complete penetrance.
The miR-1792 Cluster Is Overexpressed Specifically in Mouse and
Human MBs with a SHH Signature. All current mouse MB models
harbor a Shh/Patched signature regardless of the mutations used
to predispose it to tumor development. This suggests that the
miRNA signature obtained from tumors in our mouse models
might be similar across all models, if alterations in the SHH
pathway or those mutations that cooperate with such lesions
exert dominant effects on miRNA expression. Because only
humanMBs with a SHH signature expressed individual miRNAs
from the miR-1792 cluster, other subgroups of human MBs
with unknown mutations or mutations in the WNT pathway may
express a distinct subset of miRNAs that contribute to tumor
development in that genetic setting. Thus future prospective
analysis of miRNAs on a larger cohort of human MBs with
different gene signatures might provide a more refined analysis
Table 1. Enforced expression of the miR-1792 cluster in GNPs
from Ink4c/; Ptch1/ but not Ink4c/; p53/ mice
induces medulloblastoma
Plasmids Ink4c/; Ptch1/ Ink4c/; p53/
Control (MSCV or MLS
empty vector)
5/15 (2.5–4 months) 0/10
miR-1792 9/9 (1.5–5 months) 0/4
miR-106a92 0/5 0/4
miR-21 0/3 0/6
N-Myc 6/7 (1–4.5 months) 11/17 (1.5–6 months)
c-Myc 8/8 (1.5–4 months) 16/21 (1–2.5 months)
Cyclin D1 3/6 (3–6 months) 2/5 (3.5 months)
Cyclin D2 5/6 (2–4.5 months) 1/5 (6.5 months)
Fig. 4. Molecular characterization of ‘‘engineered’’ MBs in mice after en-
forced expression of the miR-1792 cluster in GNPs from P6 Ink4c/;
Ptch1/mice. Enforced expression ofmiR-1792 in P6 GNPs from Ink4c/;
Ptch1/ mice induced MBs in recipient mice. QRT-PCR analysis was per-
formed in (A) and (B) using RNA extracted from purified GNPs from P6 mouse
cerebella, 1-month (1M) whole mouse cerebellum, and GNP-like tumor cells
from MBs engineered and spontaneously arising in Ink4c/; Ptch1/mice
(MB 65939) (the numbers indicate the recipient mice). (A) miR-1792 expres-
sion in induced tumors was confirmed by analysis of selected individual
microRNAs from the cluster (miR-19a, miR-92). (B) Induced tumors express
high levels of Math1 and Gli1 mRNA. (C) GNP-like tumor cells overexpressing
the miR-1792 cluster remain sensitive to cyclopamine: tumor cells from 2
independently derived MBs (tumor nos. 64199 and 64389) treated or not with
cyclopamine were measured for proliferation by BrdU incorporation (Left
panel) and for expression of Gli1 and Math1 RNA expression by QRT-PCR
(Right panel).











and might provide not only prognostic value but also clues to the
full range of miRNAs that impact human MB.
Functional Interrelationship Between Patched Signaling and the miR-
1792 Cluster. Purified GNPs from P6 Ink4c/; Ptch1/mice
infected with a GFP-expression control retroviral vector gave
rise to rare MBs when orthotopically implanted into recipient
animals. These tumors occur with low penetrance. This strongly
argues for an impact of stochastic secondary mutations that
transform a subset of transplanted cells irrespective of whether
they had or had not integrated the viral vector.
In stark contrast, similar GNPs engineered to ectopically
express miR-1792 by retroviral transfer developed into MBs
following transplantation with complete penetrance in 9/9 re-
cipient mice. Interestingly, enforced expression of the miR-
10625b paralog, which maps to chromosome X, never gave rise
to MBs. This finding is consistent with the fact that this paralog
is expressed at low or negligible levels in GNPs and MBs and
suggests that lower expression is not determined by the endog-
enous promoter of this cluster alone but also by posttranscrip-
tional mechanisms (30). miR-21 has been shown to be overex-
pressed in many human tumors; however, it was not expressed at
all during cerebellum development or in tumors, suggesting
specificity in the nature of prooncogenic microRNAs that can
contribute to tumor development in the cerebellum. Consistent
with the implications of expression profiling, ectopic expression
of miR-21 in GNPs from the cerebella of P6 Ink4c/;
Ptch1/ mice did not induce tumors.
Ink4c; p53 doubly deficient mice sometimes spontaneously
develop MBs. In this genetic context, overexpression of miR-
1792 in GNPs from the cerebella of P6 mice with this genotype
did not induce tumors above this background level upon trans-
plantation of engineered cells into the cortices of recipient mice.
Enforced expression of miR-1792 did efficiently cooperate
with Patched loss to induce tumors with complete penetrance,
arguing strongly for a functional link between the Patched
pathway and this microRNA cluster.
Because we were unable to convincingly show that any of the
previously reported targets, including PTEN, were affected at
the protein level by ectopic expression of miR-1792, it is not at
present possible to propose a specific molecular mechanism by
which miR-1792 affects the phenotype of GNPs. Our data
support the idea that loss of Patched is necessary formiR-1792
to exert its tumorigenic effect. This could be the result of a direct
or indirect interaction between a gene that is activated by SHH
signaling, including N-Myc, Gli1, Math1, or other genes, and
miR-1792. One could envision several models by which coop-
eration could occur. For example, (i) miR-1792 could repress
target(s) that otherwise buffer or counteract the oncogenic
signals emanating from the SHH pathway or (ii) miR-1792
could amplify the effects of SHH signaling, perhaps by inhibiting
a transcriptional repressor of a subset of SHH target genes. In
this case, these genes would be activated only when both SHH
signaling is on and miR-1792 is inhibiting the repressor.
Patched might also impact the transcription of themiR-1792
cluster directly, with loss of Patched through Gli1 or other Shh
mRNA targets upregulating miRNA expression. While this
could explain the specific overexpression of the cluster in tumors
with activated SHH signaling, it is difficult to rationalize this
hypothesis with the fact that activated SHH signaling is required
to uncover the oncogenic effects of miR-1792 in GNPs.
miR-1792 might repress genes that induce cell cycle arrest
and/or differentiation or in turn be regulated by such growth
arrest and differentiation pathways. In accord with this idea, we
previously found that BMP-2, -4, and -7 oppose Shh/Ptch-
induced proliferation of GNPs and MBs, by inducing their
differentiation and the downregulation of genes in this pathway
in mouse and human MBs, but only in tumors with a SHH
signature (31). Thus, BMPs might repressmiR-1792 levels and
thus prevent promotion of MB development.
Whether miR-1792 is required for the initiation, progres-
sion, and/or maintenance of the disease will require experiments
that address the consequences of lost miR-1792 function.
Unfortunately, primary GNPs cannot be efficiently transfected
or electroporated, preventing effective suppression of miR-
1792 by antagomirs. Experiments using miR-1792-f loxed
mice in whichmiR-1792 can be conditionally deleted by the Cre
recombinase (21) will enable us to test whether miR-1792 is
essential for GNP proliferation and tumor development when
Ptch1 is mutated.
miR-1792 Is a Myc Target. Myc is one of the most potent
oncogenic agent in human cancers. Interestingly, N-Myc is
expressed at high levels in all MBs from our mouse models,
suggesting that N-Myc could activate the miR-1792 cluster in
cerebellar development and MBs. We found that enforced
expression of N-Myc or c-Myc in primary purified GNPs from
cerebella of P6 Ink4c/; Ptch1/ mice induces MBs after
orthotopic transplant in the cortices of recipient animals (Table
1). The miR-1792 cluster is a direct c-Myc target (32) and
collaborates with c-Myc in B cell lymphoma development (19).
In this context,miR-1792may provide cells with a proliferative
advantage by preventing cell cycle exit or differentiation and
thus collaborate with oncogenic signals to transform GNPs, but
would not be oncogenic on its own.
Conclusions
Although the exact mechanism by which Patched and miR-
1792 collaborate during cerebellar development and in MB
formation is still unclear, future studies on miR-1792 regula-
tion and the targets that it regulates are warranted, both by
expression studies in mouse and human MBs and by functional
studies in mice. Our findings indicate that antigomirs to the
miR-1792 cluster might provide a potential new therapeutic
strategy for patients with MBs harboring a constitutively acti-
vated SHH/PATCHED signaling pathway.
Methods
MB Patients’ Samples. Human MB samples were previously molecularly char-
acterized (13).
Animal Husbandry and Mouse Tumor Samples. Breeding and genotyping of
mice were done as reported previously (22). Mice were housed in an accredited
facility of the Association for Assessment of Laboratory Animal Care in accor-
dance with National Institutes of Health guidelines. The Animal Care and Use
Committee of St. Jude Children’s Research Hospital approved all procedures.
Mice exhibiting signs of illness (abnormal head movements, cranial expansion,
reduced activity, or ataxia) were killed. Tumors were removed and a portion
was used for purifying tumor cells. In parallel, a piece of tumor was fixed in
10% neutral-buffered formalin, embedded in paraffin, and subjected to
histopathology and immunohistochemistry analysis.
Isolation of Small RNAs and miRNAs, Sequencing, and Data Analysis. Total RNA
from GNPs, GNP-like tumor cells, and tissues was extracted using Trizol with an
extra chloroform wash and precipitated with isopropanol. Five micrograms
(g) of total RNA were used to amplify and sequence small RNAs as described
previously (33), with the introduction of a barcoded multiplexed strategy.
RNA adapters ending with a 6-nt barcode followed by a 6-nt constant region
were used in the 5-ligation step. Resulting miRNA libraries were PCR ampli-
fied with primers containing Illumina adapter sequences, such that the miRNA
would be read in reverse complement followed by the barcode sequence,
mixed into pools of 10 libraries with different barcodes, and sequenced on
Illumina sequencers. Lack of barcode bias was confirmed by amplifying and
sequencing a HeLa sample with the 10 different barcodes. The reads were
deconvoluted by barcode, collapsed to unique sequences, aligned to the
genome, and annotated. Read counts for miRNA sequences were cubic-spline
normalized then log transformed. The R-project software (http://www.R-
project.org), including Bioconductor were used for data analysis. For identi-
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fication of up- and downregulated miRNAs in tumors and P6 GNPs versus adult
cerebella, the Bioconductor package linear modeling for microarray (limma)
was used to build a model of tumor and P6 GNP samples contrasted against
adult cerebella. P-values from limma were transformed to Q-values for esti-
mation of the false discovery rate (FDR). The set of miRNAs corresponding to
a 1% FDR were filtered to require a 4-fold change between the groups. The
remaining 50 miRNAs were considered significantly different in the adult
cerebella relative to the tumor and P6 GNP samples. For sequences, see
Methods, SI Text (Fig. S4). For expression profiling, the normalized read counts
for miRNAs encoded by miR-1792 cluster family were collected, while un-
detected sequences were scaled to the minimum count of the data set.
GNP and GNP-Like MB Tumor Cell Purification, Retroviral Infection, Orthotopic
Injections, and Tumor Cell Cultures. Purification of GNPs from mouse cerebella
and MBs were done as described (22). Infection of GNPs and orthotopic
injections were carried out as described using 2  106 cells (27). To assess the
infection efficiency, 3  105 infected cells were cultured for 48 h, then fixed
and immunostained with anti-GFP. In each experiment, the infection effi-
ciency was at least 30%. MicroRNAs were cloned into a MSCV-SV40 promoter-
green fluorescent protein (GFP) vector (19). Tumor cells were purified, cul-
tured, and treated with cyclopamine, as previously described (31).
Quantitative Real-Time PCR.Quantitative real-time reverse transcriptase PCR
(QRT-PCR) for Ptch1, Math1, and Gli1 on RNA extracted from purified
GNP-like tumor cells was done as described (22). QRT-PCRs for miR-19a,
miR-92, and miR-20 were performed using Applied Biosystems TaqMan
MicroRNA assays according to manufacture’s recommendations (ABI, Fos-
ter City, CA). Briefly, cDNAs were synthesized from total RNA using miRNA-
specific primers according to the TaqMan MicroRNA reverse transcription
protocol. Reverse transcription was performed using the following pro-
gram: 30 min at 16 °C, 30 min at 42 °C, 5 min at 85 °C, and then held at 4 °C.
Q-PCR on the cDNAs was performed using a 7900HT sequence detection
system and the TaqMan Universal MasterMix reagents. Cycling conditions
were 10 min at 95 °C, followed by 40-cycle amplification for 15 sec at 95 °C
and 1 min at 60 °C. The internal RNU6B RNA levels were used for normal-
ization. Each measurement was performed in triplicate. Data were ana-
lyzed with SDS version 2.0 software (ABI).
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